3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
4
Phase 1/2
3
Phase 3
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
16
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Carcinoma, Hepatocellular
6
Kidney Neoplasms
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
Nivolumab
×
Clear all
NCT03383458
2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3
Active not recruiting
545 enrolled
NCT04340193
2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3
Completed
26 enrolled
15 charts